FFM
ONC

Fairmount Funds Management’s BeOne Medicines Ltd ONC Stock Holding History

Fairmount Funds Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-239,443
Closed -$51.6M – 19
2023
Q1 		$51.6M Hold
239,443
– – 8.88% 4
2022
Q4 		$52.7M Buy
239,443
+153,043
+177% +$28.1M 8.35% 4
2022
Q3 		$11.6M Sell
86,400
-25,000
-22% -$4.29M 2.05% 19
2022
Q2 		$18M Buy
+111,400
New +$17.4M 4.13% 11

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Fairmount Funds Management's ONC Position: Q2 2023 in Review

Fairmount Funds Management sold out of BeOne Medicines Ltd (ONC) in Q2 2023, closing a stake of 239,443 shares — an estimated $51.6M sold.

Fairmount Funds Management first reported a position in ONC in Q2 2022 and held it in 4 quarters. The position peaked at $52.7M in Q4 2022. 208 funds tracked by Wall St. Rank hold ONC as of Q2 2023.

  • Fairmount Funds Management reported no remaining BeOne Medicines Ltd position as of Q2 2023 after selling out during the quarter.
  • Fairmount Funds Management sold 239,443 BeOne Medicines Ltd shares in Q2 2023, an estimated $51.6M.
  • Fairmount Funds Management first reported a position in BeOne Medicines Ltd in Q2 2022 and held it in 4 quarters.
  • Fairmount Funds Management's BeOne Medicines Ltd position peaked at $52.7M in Q4 2022.
  • 208 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2023.

Based on Fairmount Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.